Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men
AUTOR(ES)
Sudhop, Thomas
FONTE
The American Society for Biochemistry and Molecular Biology
RESUMO
This study evaluates changes in cholesterol balance in hypercholesterolemic subjects following treatment with an inhibitor of cholesterol absorption or cholesterol synthesis or coadministration of both agents. This was a randomized, double blind, placebo-controlled, four-period crossover study to evaluate the effects of coadministering 10 mg ezetimibe with 20 mg simvastatin (ezetimibe/simvastatin) on cholesterol absorption and synthesis relative to either drug alone or placebo in 41 subjects. Each treatment period lasted 7 weeks. Ezetimibe and ezetimibe/simvastatin decreased fractional cholesterol absorption by 65% and 59%, respectively (P < 0.001 for both relative to placebo). Simvastatin did not significantly affect cholesterol absorption. Ezetimibe and ezetimibe/simvastatin increased fecal sterol excretion (corrected for dietary cholesterol), which also represents net steady state cholesterol synthesis, by 109% and 79%, respectively (P < 0.001). Ezetimibe, simvastatin, and ezetimibe/simvastatin decreased plasma LDL-cholesterol by 20, 38, and 55%, respectively. The coadministered therapy was well tolerated. The decreases in net cholesterol synthesis and increased fecal sterol excretion yielded nearly additive reductions in LDL-cholesterol for the coadministration of ezetimibe and simvastatin.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2739752Documentos Relacionados
- Effects of neomycin on absorption, synthesis, and/or flux of cholesterol in man.
- COMPETING SOLVENT EXTRACTION OF CALCIUM AND/OR NICKEL WITH CYANEX 272 AND/OR D2EHPA
- Your money and/or your life?
- Greater systemic lipolysis in women compared with men during moderate-dose infusion of epinephrine and/or norepinephrine
- Interferon Induction and/or Production and Its Suppression by Influenza A Viruses†